EGFR mutations were more frequent in tumours with CTR ranging from 0.25 to 0.5 (85.7%, 12/14) and from 0.5 to 1 (66.7%, 20/30) than in those with CTR ranging from 0 to 0.25 (51.0%, 25/49) (P=0.048) (Table 2). Here, EGFR is linked to neoplasm.